Senior Scientist

Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.

Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.

Zymergen

Senior Scientist, RNA Therapeutics

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team‚Äôs deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.

Structure Therapeutics

Senior Scientist, Pharmacology

SpringWorks Therapeutics is a biopharmaceutical company focused on developing medicines for patients with severe rare diseases and cancer.

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks‚Äô strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.

SpringWorks Therapeutics

Discovery Chemistry Senior Scientist II

Translational Medicine Senior Scientist

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Entrada Therapeutics‚Äô mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada‚Äôs technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.

Entrada Therapeutics

Senior Scientist, Bioanalytical

Capstan Therapeutics is advancing cell engineering to develop therapeutics for a broad range of diseases.

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Capstan Therapeutics

Scientist II/Senior Scientist, Analytical Operations (AMD)

Arranta Bio is a superior Contract Development Manufacturing Organization.

Arranta Bio was formed in May 2019 with the vision to be the best-in-class microbiome CDMO, developing and manufacturing live biotherapeutic products (LBPs) for pioneers targeting diseases linked to the microbiome, using bacterial fermentation, isolation, drying and encapsulation. In October 2019, we completed an $82,000,000 funding round with sole institutional investor, Ampersand Capital, company founders and colleagues, and a strategic investment from Thermo Fisher Scientific.

Location

Company Stage

Age of Data

Experience

Industry

Company